UNCOVERING THE LYSOSOMAL ROLE OF PROGRANULIN by Pagan, Mitchell
i 
 
 
 
 
 
 
 
 
UNCOVERING THE LYSOSOMAL ROLE OF PROGRANULIN  
 
 
 
 
 
 
 
A Thesis 
Presented to the Faculty of the Graduate School 
of Cornell University 
in Partial Fulfillment of the Requirements for the Degree of 
Master of Science 
 
 
 
 
 
 
 
By Mitchell Douglas Pagan 
May 2019 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 Mitchell Douglas Pagan 
iii 
 
ABSTRACT 
 
Lysosomes are the degradative centers of the cell and their dysfunction can give rise to lysosomal 
storage disorders (LSDs). Frontotemporal lobar degeneration (FTLD) is a neurodegenerative 
disease that exhibits the features of LSDs: the aggregation of proteins in endolysosomal 
compartments and a decrease in lysosomal activity. One of the genetic causes of FTLD has been 
traced back to the haploinsufficiency of progranulin (PGRN), a secreted glycoprotein comprised 
of seven and one-half granulin repeats. PGRN can also be processed into discrete granulin 
peptides, each with its own potential function. PGRN has been shown to be critical for proper 
lysosome function, but the mechanism is still unclear. Since PGRN’s link to FTLD was 
established, TMEM106B, a lysosomal transmembrane protein, has been identified as a risk factor 
for FTLD patients with GRN mutations (FTLD-GRN). TMEM106B levels are increased in cases 
of FTLD-GRN and the overexpression of TMEM106B results in lysosome enlargement and an 
increase in transcription factor EB-dependent (TFEB) lysosomal exocytosis.  TFEB is the 
transcription factor responsible for the expression of most genes associated with lysosomal 
biogenesis and its transcriptional activity is increased in ΔGRN cells. Since an increase in TFEB 
activity is linked to an increase in exocytosis, I hypothesized that the depletion of PGRN results 
in an increase in lysosomal exocytosis. I assessed whether lysosomal exocytosis is increased in 
PGRN deficient cells and, while early results showed an increase in exocytosis, further testing 
generated results that were inconclusive. Proteomic screens to identify binding partners for 
PGRN and granulin peptides were also carried out, but the procedures need to be optimized. 
Since this testing was completed, researchers have published data that confirms an increase in 
lysosomal exocytosis in the absence of GRN. This increase in lysosomal exocytosis should be 
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further characterized by profiling the full spectrum of functional lysosomal enzymes that are 
excreted into the extracellular space and whether these enzymes negatively impact surrounding 
neurons. These findings could uncover a mechanistic link between GRN mutation, FTLD, and 
the onset of dementia.  
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CHAPTER ONE:  INTRODUCTION 
 Lysosomes are the center of degradation and recycling in the cell, harboring a diverse 
array of enzymes to carry out their function; other lysosomal functions include exocytosis, 
nutrient sensing, and autophagy [37]. Lysosomal function and cellular degradative capacity are 
therefore inextricably linked. The absence or dysfunction of lysosomal proteins, whether 
enzymatic or not, can result in lysosomal storage disorders (LSDs) [37, 47]. LSDs are 
characterized by a decrease in lysosomal activity and the aggregation of proteins in 
endolysosomal organelles [37, 47]. One disease that exhibits the typical hallmarks of LSDs is 
frontotemporal lobar degeneration (FTLD). 
 FTLD is a neurodegenerative disease and second leading cause of early-onset dementia 
behind Alzheimer’s disease (AD) [50]. It generally manifests as microvacuolation of the brain, 
nerve cell loss, expansion of ventricles, and atrophy of the frontal and temporal lobes [8, 16, 41, 
69]. The severity and prevalence of FTLD has garnered considerable attention from the research 
community, but the disease mechanism has remained elusive. A lot of the difficulties in studying 
FTLD arise from the diverse nature of the disease. FTLD can be divided into subgroups based 
upon the proteins associated with the inclusion bodies. These protein aggregates can be 
comprised of TAR DNA-binding protein (TDP-43), tau protein, or fused in sarcoma protein [36]. 
Genetic studies have also revealed that mutations in multiple genes can lead to FTLD. Among 
the most characterized FTLD-related genes are GRN, MAPT, and C9orf72 [49].  
 Genetic studies, in conjunction with biochemical analyses, uncovered the link between 
heterozygous mutations in GRN, the product of which is progranulin (PGRN), and the onset of 
FTLD (FTLD-GRN) [14, 18, 36, 39]. Mutations in GRN are associated with tau-negative, 
ubiquitin-positive FTLD, of which TDP-43 is typically aggregated [14, 18, 36, 39]. GRN 
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mutations were found in 10% of the FTLD population and in 23% of familial cases [18]. It was 
determined that these mutations lead to a haploinsufficiency of PGRN, with most mutations 
resulting in truncated transcripts [14, 18, 39]. So far, more than 60 mutations in GRN have been 
associated with FTLD [49]. Interestingly, homozygous mutations were later discovered to be the 
underlying cause of neuronal ceroid lipofuscinosis (NCL), another LSD [2, 56]. FTLD and NCL 
both display an upregulation of lysosomal proteins, lipofuscinosis, and the accumulation of tau-
negative, ubiquitin-positive TDP-43 [19, 30, 68]. This suggested that FTLD could represent a 
milder form of NCL and that the effects of GRN mutations are dose-dependent. It also began to 
solidify the role of PGRN in the lysosome.  
 PGRN is a secreted glycoprotein consisting of seven and one-half repeats of a cysteine-
rich, β-hairpin stack motif (Figure 1a) [7, 25, 57, 60, 61, 67]. The motifs are connected by short 
linker regions that are more flexible than the rigid granulins and individual granulin motifs (or 
peptides) occur naturally [4, 25, 60, 61]. The release of these granulin peptides can occur 
extracellularly by matrix metalloproteinases and neutrophil elastase or within the lysosome by 
cathepsin L (CathL) (Figure 1b).   PGRN is expressed in epithelial cells, immune cells, and 
cortical neurons, but very little PGRN is detected in muscle and connective tissue [15]. Its 
conservation across taxa and expression in unicellular eukaryotes suggests that it has a 
fundamental role in the cell [45].  While some researchers have implicated PGRN and granulin 
peptides in processes of growth and inflammation, the function of PGRN has largely remained a 
mystery [20-23, 34, 35, 40, 48, 55, 71]. It has also been proposed that full-length PGRN and the 
granulin peptides can act in opposition to one another; some even found that individual granulin 
peptides have contrasting functions [21-23, 48, 51, 55]. In an attempt to more clearly elucidate 
the function of PGRN many researchers have now turned their focus to the lysosome.  
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 After its connection to LSDs, PGRN’s status as a lysosomal protein has been expanded 
upon. Predictive models based on protein interactions suggested that PGRN resides in the 
lysosome and its subcellular residence was confirmed by the colocalization of PGRN with 
lysosomal markers (e.g. LAMP1, CD68) [6, 26, 40]. PGRN can be trafficked to the lysosome 
from the trans-Golgi network or from the extracellular space by sortilin, a sorting receptor highly 
expressed in neurons (Figure 1b) [26, 73]. PGRN can also bind another resident lysosomal 
protein, prosaposin (PSAP), for trafficking to the lysosome [75-77]. In this instance, PGRN binds 
PSAP and then PSAP binds a mannose-6-phosphate receptor (MPR) for their subsequent 
delivery. PSAP can reciprocally hitch a ride with PGRN through the sortilin receptor pathway 
[76]. Once in the lysosome, PGRN binds cathepsin D (CathD) and aids in its maturation from 
inactive proCathD to catalytically active matCathD [5, 11, 62]. It has also been shown to act as a 
co-chaperone that binds β-glucocerebrosidase (GCase), a lysosomal enzyme important in 
glycolipid metabolism [27]. Loss of PGRN results in the aggregation of GCase and a decrease in 
its activity (unpublished) [27]. 
 While PGRN’s localization, binding partners, and function demonstrate that its primary 
role exists in the lysosome, its regulation by and of transcription factor EB (TFEB) strengthens 
this case. TFEB is responsible for the transcription of a majority of the genes necessary for 
lysosomal biogenesis, also known as the Coordinated Lysosomal Expression and Regulation 
(CLEAR) network of genes [53]. When overexpressed, TFEB leads to the upregulation of 
lysosome formation and a rise in degradative capability [53]. Along with these broad effects, the 
overexpression of TFEB results in a significant increase in PGRN levels [6]. Conversely, when 
PGRN is overexpressed the lysosomal genes under the control of TFEB are upregulated [6].  
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 While great headway has been made in understanding the lysosomal importance of 
PGRN, the study of PGRN in relation to FTLD has been complicated. Recapitulating FTLD in 
mice has proven difficult and GRN homozygous mutants do not display an obvious phenotype 
[1]. However, homozygous GRN mutant mice display the phenotypes associated with FTLD: 
ubiquitin-positive lipofuscin accumulation, hyperphosphorylated TDP-43 inclusions, reduced 
autophagic flux, behavioral deficits, and decreased life expectancy [1, 12, 70, 72]. Despite the 
difficulties, additional proteins related to FTLD-GRN have been identified and the big picture, 
while becoming more complicated, is starting to be revealed.  
 Transmembrane protein 106B (TMEM106B) was identified in a GWAS of FTLD-TDP 
patients as a risk factor for FTLD-GRN [64]. When compared to FTLD-TDP, FTLD-GRN 
patients had a higher expression of TMEM106B [64]. Researchers also discovered that three 
TMEM106B single nucleotide polymorphisms (SNPs) were able to modulate the penetrance of 
FTLD-GRN, each with a risk and, less common, protective allele [17, 43, 64, 66]. Only one of 
the SNPs manifests as a coding variant, T185S [17, 43, 64]. This variant is in linkage 
disequilibrium with the other SNPs and the expression of the risk allele results in an increase in 
TMEM106B when compared with the protective allele [13, 17, 43, 64]. Whether the increase in 
TMEM106B is due to an increase in transcription, a decrease in degradation, or both is disputed 
[29, 43, 64]. 
 TMEM106B is a type-II transmembrane protein that localizes to endolysosomal 
compartments [9, 13, 32, 58].  Its entire structure has not been solved, but researchers have 
determined that its cytosolic N-terminus is intrinsically disordered [28]. Like most lysosomal 
membrane proteins, TMEM106B’s lumenal domain is glycosylated and two of the five sites are 
crucial for proper sorting into the endolysosomal pathway [32, 58]. While little is known about 
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its purpose within the cell, researchers have consistently demonstrated abnormal lysosomal 
phenotypes in the absence and overexpression of TMEM106B. When its expression is 
upregulated, TMEM106B causes an increase in the size of lysosomes while lysosomes decrease 
in number; this increase in lysosome size is accompanied by a decrease in degradative capacity 
[9, 10, 13]. An increase in expression is also associated with the trafficking of lysosomes to the 
periphery of the cell and an increase in lysosomal exocytosis [31, 54]. The opposite is true when 
TMEM106B is knocked down, with lysosomes decreasing in size and clustering in the 
perinuclear region [54, 58]. 
The mechanism by which TMEM106B can alter the morphology and positioning of 
lysosomes has not been pinned down, but what we do know is that TMEM106B can influence 
the activity of TFEB. Along with increasing lysosomal biogenesis, upregulation of TFEB also 
stimulates lysosomal exocytosis [38]. Scientists have shown that the overexpression of 
TMEM106B causes the translocation of TFEB from the cytoplasm to the nucleus, an 
upregulation in lysosomal genes, and an increase in lysosomal exocytosis [31, 58]. The 
knockdown of TFEB is able to rescue these lysosomal phenotypes when TMEM106B is 
overexpressed [31]. While much work is still needed to identify TMEM106B’s exact function, it 
undoubtedly plays a role in the lysosome.  
 Since, the loss of GRN increases the activity of TFEB and the overexpression of 
TMEM106B results in an increase in TFEB-dependent lysosomal exocytosis, I hypothesized that 
lysosomal exocytosis is increased in ΔGRN cells [13, 31, 43, 59, 64]. I assessed lysosomal 
exocytosis by observing the translocation of TFEB to the nucleus, the deposition of lysosomal 
markers on the plasma membrane, and the release of lysosomal enzymes into the extracellular 
space. While early experiments revealed that lysosomal exocytosis was indeed increased in 
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ΔGRN cells, the results became inconclusive after revisiting many of the assays. To open up 
other avenues of research, I also pursued potential interacting proteins for PGRN and individual 
granulin peptides through stable isotope labeling with amino acids in cell culture (SILAC) and 
biotinylation by antibody recognition (BAR) techniques. While the SILAC experiments have not 
returned any additional hits, I believe that the BAR technique can be optimized and successfully 
used in the future. Since, completing these preliminary experiments, researchers have 
documented an increase in lysosomal exocytosis in ΔGRN cells  [42]. If this increase in 
lysosomal exocytosis in ΔGRN cells is real, the lysosomal enzymes that are expelled into the 
extracellular space should be characterized and assessed for activity. The release of functional 
enzymes into the extracellular space could have detrimental effects on neighboring cells and 
could provide a link between PGRN haploinsufficiency and FTLD.  
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CHAPTER TWO:  RESULTS 
 
Loss of GRN may induce an increase in lysosomal exocytosis 
 It has been established that TMEM106B overexpression leads to the translocation of 
TFEB to the nucleus, an increase in lysosomal biogenesis, and the induction of lysosomal 
exocytosis [31, 58]. Researchers have also shown that this increase in lysosomal exocytosis is 
dependent on TFEB [31]. TMEM106B is a modulator of FTLD-GRN penetrance, with higher 
expression correlated with greater TDP-43 accumulation [43, 63, 64]. Therefore, it stands to 
reason that general lysosomal dysfunction in concert with higher levels of TMEM106B could 
lead to lysosomal exocytosis in the case of FTLD-GRN.  
To assess lysosomal exocytosis in a ΔGRN background, I used ΔGRN RAW cells, a 
murine macrophage line, that our lab had previously generated.  Since the documented increases 
in lysosomal exocytosis were driven by TFEB, I first assessed whether TFEB localization 
changed in ΔGRN cells. At first, it was clear that control cells had a cytosolic distribution of 
TFEB, with little evidence of translocation of TFEB to the nucleus (Figure 2a). On the other 
hand, the majority of ΔGRN cells had a strong TFEB signal that colocalized with the nucleus. 
Very few ΔGRN cells showed the same cytosolic distribution of TFEB that was seen in the 
control cells. However, as trials were repeated, more of the control cells began to show a nuclear 
localization of TFEB (Figure 2b).  
While some documented increases in lysosomal exocytosis are dependent upon TFEB, 
the translocation of TFEB to the nucleus does not demonstrate that lysosomes are fusing with the 
plasma membrane and expelling their contents into the extracellular space. To assess lysosomal 
fusion with the plasma membrane, we observed the deposition of LAMP1, a lysosomal marker, 
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on the plasma membrane. If exocytosis is increased, an increase of surface LAMP1 staining 
should observed. Compared to control cells, ΔGRN cells show an increase in LAMP1 signal on 
the plasma membrane (Figure 3a). Again, as time went on and experiments were repeated, this 
difference became negligible, with control cells showing a similar distribution of LAMP1 to 
ΔGRN cells (Figure 3b).  
An increase in LAMP1 at the plasma membrane could represent an increase in lysosomal 
exocytosis, but this does not rule out a trafficking or endocytic defect. We decided that a more 
definitive measure of exocytosis would be to measure lysosomal proteins in the extracellular 
space. If exocytosis is increased, lysosomal proteins should be more abundant in the conditioned 
media of ΔGRN cells. Cathepsins, a major class of lysosomal proteases, were slightly increased 
in the lysates of ΔGRN cells, consistent with the documented upregulation of lysosomal genes in 
the absence of GRN (Figure 4). Interestingly, cathepsins were also increased in the conditioned 
media of ΔGRN cells. It is worth noting that the most of the cathepsins in the extracellular space 
are present in their unprocessed, pro-form.  
 
The identification of binding partners for full-length progranulin and granulin peptides 
 Scientists have proposed functions for a few granulin peptides, but the binding partners 
and precise role of each granulin is largely unknown [4, 48, 55, 60]. Pulling down and detecting 
granulin peptides has been an issue in the past, but our lab has optimized conditions so that 
immunoprecipitation (IP) of the peptides is feasible. To identify novel interactions between 
progranulin or granulin peptides, we performed SILAC and BAR experiments. 
Granulin constructs 
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At first, we thought it would be beneficial to create GFP-tagged granulin peptides to 
individually transfect into ΔGRN cells, so that the subsequent IP would result in binding partners 
specific to each granulin peptide (Table 1). The cloning of each granulin construct was successful 
and the expression of each peptides was detectable in cell lysates and conditioned media (Figure 
5). However, when transfected into cells, the granulin peptides showed an erratic distribution. 
Some peptides were completely cytosolic and others formed large aggregates (data not shown). 
Some peptides even showed a mix between diffuse and aggregated signal that differed from cell 
to cell. More importantly, the colocalization of granulin peptides with lysosomal markers was 
minimal. In light of these results, we decided to assess the binding partners of endogenous PGRN 
and granulin peptides. 
SILAC of PGRN and granulin peptides 
 Sheep anti-PGRN beads were created and shown to be specific and capable of pulling 
down full-length PGRN and granulin peptides (data not shown). Control and ΔGRN RAW cells 
were grown in carbon-13 heavy and carbon-12 light media, respectively. The IP of PGRN was 
efficient for the cell lysate, but the beads failed to IP PGRN or granulin peptides in the 
conditioned media (Figure 6). The silver stain of the lysates showed that the IP was relatively 
clean, so the samples were prepared for and analyzed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Due to contaminants and lack of granulin peptides in the acquired 
data set, no conclusions could be drawn (data not shown).  
Lysosomal isolation for the enrichment of granulin peptide interactors 
 PGRN undergoes cleavage events in the lysosome that release individual granulin 
peptides, so we thought it would be useful to enrich for granulin peptides prior to the 
identification of interactors [24, 33, 74]. Since granulin peptides should not be present in other 
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intracellular compartments, identified proteins should be more likely to bind granulin peptides 
and not full-length PGRN than if whole cell lysate was used.  
 Before the technique was used for the identification of binding proteins, I first set out to 
optimize the conditions of lysosomal isolation with wild-type (WT) mouse liver samples. 
Following the manufacturer’s protocol resulted in fairly distinct layers, but there appeared to be 
an abundance of endoplasmic reticulum (ER) contamination. Gradients have been optimized for 
different tissue and cell types, so a modified gradient based on the literature was assessed for 
recovery and elimination of contaminants (Figure 7a) [44, 52]. While the recovery was 
unaffected, the modified gradient seemed to produce more distinct bands and the ER 
contamination was slightly reduced (Figures 7b and 7c). Further optimization will be necessary 
for any proteomic or quantitative analyses. 
Identification of PGRN and granulin peptides binding partners through BAR 
 In conjunction with the SILAC analyses, I attempted to identify potential PGRN 
interactions through the use of the BAR technique as previously described [3]. For the 
identification of binding proteins, horseradish peroxidase (HRP) is targeted to the protein of 
interest with antibodies. Biotin is then added to the reaction, so that HRP can link biotin to 
proteins in the vicinity of the protein of interest. These surrounding proteins can then be pulled 
down with streptavidin. Identified proteins do not necessarily bind the protein of interest and any 
hits would have to be confirmed with additional analyses, but this method could be useful in 
identifying interactions that may be more transient.  
 Before the application of this method, I set out to optimize the conditions so that labeling 
was sufficient and specific. I used the labeling of PGRN-interacting proteins in control and 
ΔGRN mouse embryonic fibroblasts (MEFs) for these purposes. Proteins that interact with 
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PGRN should be endolysosomal. The staining of biotin after labeling was strong, colocalized 
with lysosomes, and the signal was dependent on labeling time (Figure 8a). Little to no signal 
was observed in the ΔGRN condition. Since the labeling was deemed specific, I attempted to pull 
down the labeled proteins with streptavidin. The pulldown of proteins was relatively specific, 
with the control sample pulling down PSAP, a PGRN-binding protein, more readily than the 
ΔGRN condition (Figure 8b). However, the efficiency of this labeling was much lower than had 
been observed in the staining. Again, further optimization of this technique will be required 
before it is used in the identification of interactors. 
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CHAPTER THREE:  DISCUSSION 
Loss of GRN may induce an increase in lysosomal exocytosis 
 Characterizing the hallmarks of lysosomal exocytosis in ΔGRN cells resulted in some 
mixed outcomes. The translocation of TFEB to the nucleus and an increase in surface LAMP1 
were observed in ΔGRN cells in preliminary experiments, but these phenotypes became more 
inconclusive with time. Of course, the earlier phenotypes could have been a fluke and the 
repetition of experiments may have revealed a truer depiction of the difference between control 
and ΔGRN cells. However, other analysts and I noticed that these particular macrophages had 
become quite unhealthy and typically displayed an active, spread out morphology. We would 
expect to observe an increase in lysosomal biogenesis in these active macrophages. If both the 
control and ΔGRN cells were in their active states and lysosomal biogenesis genes were 
upregulated, observing a difference between the two conditions would become quite challenging. 
Indeed, the disappearance of the contrast between control and ΔGRN phenotypes closely 
coincided with our observations that the cells had become stressed. 
 Lysosomal exocytosis was also assessed by probing for lysosomal enzymes in the 
conditioned media of control and ΔGRN cells. The levels of cathepsins in the conditioned media 
were consistently higher for ΔGRN cells. One would expect to find this increase in lysosomal 
proteins in the extracellular space if lysosomal exocytosis is upregulated. However, if the origin 
of these cathepsins is lysosomal, they should be in their mature form. The cathepsins in the 
conditioned media of both control and ΔGRN cells were in their unprocessed, inactive forms. 
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Instead of lysosomal exocytosis, the observed difference between the two conditions could arise 
from a change in the trafficking of the enzymes of interest.  
 While this work was being completed, a report was published describing an increase in 
lysosomal exophagy in ΔGRN macrophages [42]. Exophagy is a term that describes the 
breakdown of extracellular components by the enzymes residing in lysosomes. Lysosomes 
release their contents into the extracellular space, macromolecules are degraded, and the 
degraded contents are then taken up by the cell. This work mirrors the more convincing 
phenotypes I observed in ΔGRN macrophages. It seems as though an increase of lysosome fusion 
with the plasma membrane and a release of lysosomal contents into the extracellular space are 
probable in the absence of PGRN.  
 This release of lysosomal contents could serve as a disease mechanism for FTLD. An 
increase in the expulsion of lysosomal contents into the extracellular space could adversely affect 
neighboring cells. While the enzymes I probed for (i.e. CathB and CathL) were in their inactive 
forms, that does not account for all proteases or other classes of lysosomal enzymes. It would be 
interesting to see if an increase in enzymatic activity can be detected in the conditioned media of 
ΔGRN cells and whether this media impacts the health of cultured neurons.  
  
The identification of binding partners for full-length progranulin and granulin peptides 
 The search for additional interactors for both full-length PGRN and granulin peptides was 
unfruitful. Data from the SILAC experiment was inconclusive and the BAR protocol was never 
optimized to the point where a mass spectrometry analysis could be performed. While the 
pulldown of known PGRN interactors was not very efficient and contained some background 
noise, I was able to successfully amplify the signal of a target protein for imaging. This protocol 
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can be used by the lab in the future to increase the signal of proteins with low levels of 
expression. 
 The search for proteins that interact with granulin peptides will continue to be arduous. It 
is clear that the GFP-tagged granulin constructs that I created will be of little use for these 
purposes. The GFP tag is larger than the individual granulin peptides and most likely affects their 
function and localization. Creating granulin peptides with a less intrusive tag could reduce the 
unintended consequences, but their trafficking to the lysosome would still remain an issue. 
PGRN and granulin E can bind sortilin, but routes for the other granulin peptides to the 
lysosome, if they exist, are unknown [26, 73]. Granulins should not bind many proteins in the 
cell outside of the lysosome, so their delivery to this compartment is absolutely necessary. For 
these reasons, the search for granulin peptide binding partners will most likely have to be 
completed with endogenous protein.  
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CHAPTER FOUR:  FIGURES 
 
 
Figure 1: The architecture, trafficking, and processing of progranulin.  
(a) A representation of PGRN with its seven and one-half granulin repeats. The 
short linker regions are depicted in dark green. (b) A schematic of the trafficking 
of PGRN by sortilin and co-trafficking with PSAP. The cleavage of PGRN is 
shown in the extracellular space and lysosome with the respective proteases. This 
figure was adapted from Daniel Paushter [46]. 
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Figure 2: Localization of TFEB in ΔGRN RAW cells. 
Control and ΔGRN RAW cells were fixed and stained with anti-TFEB and anti-
LAMP1 antibodies, along with DAPI. (a) A representative set of images from 
earlier experiments shows that TFEB is more localized to the nucleus in ΔGRN 
cells when compared to controls. (b) A representative set of images from later 
experiments showing the loss of this difference between control and ΔGRN cells. 
Scale bars: 10µm.   
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Figure 3: Surface LAMP1 staining in ΔGRN RAW cells. 
To assess lysosomal exocytosis, live-staining of surface LAMP1 was performed 
on control and ΔGRN RAW cells. To avoid permeabilization and labeling of 
internal LAMP1, cells were incubated on ice with anti-LAMP1 antibody in 1X 
HBSS with 20mM HEPES for 2 hours. Cells were then fixed and stained with 
secondary antibody. (a) Representative images from earlier experiments that show 
an evident increase in surface LAMP1 staining in ΔGRN cells. (b) Images from 
later experiments showing a decrease in the difference in surface LAMP1 staining 
between control and ΔGRN cells. Scale bars: 10µm.   
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Figure 4: Cathepsins are increased in the conditioned media of ΔGRN RAW cells. 
The lysates and conditioned media of control and ΔGRN cells were probed for 
cathepsins with anti-CathB and anti-CathL antibodies. CathL, and to a lesser 
extent, CathB are increased in the conditioned media of ΔGRN cells. The majority 
of both cathepsins in the media are present in their pro-forms. GAPDH and 
transferrin were immunoblotted as lysate and media controls, respectively.  
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Figure 5: The expression of granulin peptides in HEK293T cells. 
GFP-tagged granulin peptides were individually transfected into HEK293T cells 
to evaluate their expression. Each of the granulin peptides was detected in the 
lysate and media. The anti-PGRN antibody was able to detect all of the granulin 
peptides, but to a lesser extent in the conditioned media.  
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Figure 6: Western blot confirmation for the SILAC of PGRN and granulin peptides. 
Control and ΔGRN cells were grown in carbon-13 heavy and carbon-12 light 
media, respectively. Anti-PGRN beads were used to IP PGRN in the lysates and 
conditioned media of each sample. PGRN was pulled down in the lysate, but very 
little PGRN was observed in the media; therefore, only the lysate samples were 
prepared for LC-MS/MS 
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Figure 7: Optimization of lysosome isolation for potential downstream processing. 
Lysosome isolation was completed as per the manufacturer’s protocol with a 
modified gradient using WT mouse liver. (a) Representation of the original, 
manufacturer-suggested gradient and the modified gradient adapted from the 
literature [44, 52]. (b) A representative sample using the modified gradient pre- 
(left) and post-centrifugation (right). (c) A Western blot showing that LAMP1, a 
lysosomal marker, was enriched in fraction 2. IB of calnexin was used to 
determine the amount of ER contamination. “Pellet” samples originate from the 
very first centrifugation step and should contain only whole cells and denser 
organelles. 
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Figure 8: BAR protocol optimization and assessment via microscopy and western blot.  
To evaluate the specificity and degree of labeling, PGRN was used as a target 
protein in control and ΔGRN MEF cells. (a) The BAR analysis was completed as 
per the manufacturer’s protocol and then stained for biotin and LAMP1. Since 
PGRN was used as the target protein, colocalization of biotin and LAMP1 should 
be observed. The labeling of samples was specific and time-dependent, with 
labeling for 5 minutes greatly increasing the signal when compared with samples 
labeled for 2 minutes. Little to no labeling was observed in the ΔGRN MEFs. 
Scale bars: 10µm. (b) The streptavidin enrichment for biotinylated proteins after 
labeling as previously described, with PGRN as a target protein [3]. If the labeling 
and pulldown were efficient, PGRN and PSAP, a known PGRN interactor, should 
be observed in the IB. PGRN and PSAP were present, but at very low levels. The 
labeling of PSAP was also only slightly higher in the control compared to the 
ΔGRN condition. Sup = supernatant.  
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Table 1: Granulin peptide constructs. 
The amino acid sequence for each granulin peptide. The constructs we created 
include the underlined amino acids. All granulin peptide constructs are tagged 
with GFP at the N-terminus. The amino acids that are not underlined represent the 
linker regions between granulin peptides. Documented cleavage sites are 
delineated by the amino acids in red [33].  
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CHAPTER FIVE:  EXPERIMENTAL PROCEDURES 
Cell Culture 
 HEK293T and MEF cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
(Corning Cellgro) with 10% FBS; RAW cells were grown in DMEM with 10% FBS and 3µg/ml 
puromycin.  All cells were kept at 37°C with 5% CO2. Transfections were carried out as 
described [65]. 
 
Plasmids 
 Mouse PGRN cDNA was obtained from Sino Biological, Inc. Granulin constructs were 
cloned into PCDH-Puro vectors (System Biosciences) in a three-way ligation with GFP using 
restriction enzymes NheI, BamHI-HF, PmeI, and SwaI (New England Biolabs, Inc.).  
 
Antibodies and Chemicals 
 Antibodies and their dilutions used are as follows: rabbit anti-TFEB (Proteintech 13372-
1-AP; IF 1:200), mouse anti-GAPDH (Proteintech 60004-1-Ig; WB 1:5000), goat anti-CathB 
(R&D Systems AF965; WB 1:500), goat anti-CathL (R&D Systems AF1515; WB 1:500), rabbit 
anti-transferrin (Proteintech 17435-1-AP; WB 1:1000), sheep anti-mouse PGRN (R&D Systems 
AF2557; WB 1:1000), rabbit anti-calnexin (Abcam ab22595; WB 1:3000), and rabbit anti-GFP 
(homemade B79D; WB 1:5000). The rabbit anti-mouse PSAP antibody used has been previously 
described (WB: 1:1,000) [76]. The hoechst (referred to as DAPI throughout the text) used for 
nuclear staining was homemade (IF 1:2000). Streptavidin 549 (Vector Labs SA-5549; IF 1:500) 
was used for the detection of biotin in the staining of BAR samples.  
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Immunofluorescence Microscopy 
 Transfections were performed two days prior to fixation. For assays not requiring 
transfection, cells were added to glass coverslips the day before fixation. Cells were washed 
twice with cold phosphate-buffered saline (PBS) and then fixed in 4% paraformaldehyde (PFA) 
for 15-20 minutes. Cells were then rinsed three times with PBS. Permeabilization of cells was 
performed with 0.05% saponin in Odyssey Blocking Buffer (LI-COR Biosciences) (OBB) for   
30 minutes. Primary antibodies in OBB with 0.05% saponin were applied to the cells overnight at 
4°C. The following day, cells were rinsed with 0.05% saponin in PBS three time for ten minutes. 
Secondary antibodies in OBB with 0.05% saponin were applied to the cells for in the dark for 
two hours at room temperature. They were then rinsed with 0.05% saponin in PBS three times 
for ten minutes. Coverslips were mounted onto slides with Fluromount-G (Southern Biotech). 
Confocal images were acquired with a ZEISS LSM 700 confocal microscope with a 100x 
objective. Images were analyzed with SlideBook 6 (3i – Intelligent Imaging Innovations) 
software.  
   
Live-Cell Staining  
 While on ice, the media was removed and the cells were rinsed twice with cold PBS. 1X 
Hanks’ balanced salt solution (HBSS) with 20mM HEPES containing primary antibodies was 
added to the cells and incubated on ice for 2 hours. Cells were then rinsed twice with cold 1X 
HBSS with 20mM HEPES and then fixed with cold 4% PFA for 15-20 minutes. Cells were then 
rinsed three times with PBS. Cells were blocked in OBB (with or without 0.05% saponin) for 30 
minutes. Secondary antibodies in OBB (with or without 0.05% saponin) were applied to the cells 
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for 2 hours at room temperature in the dark. Coverslips were rinsed three time with PBS and then 
mounted onto slides with Fluoromount-G. 
 
Trichloroacetic Acid (TCA) Precipitation of Conditioned Media 
 First, 900µl of conditioned media was collected and centrifuged for 10 minutes at 
14000rpm at 4°C. The supernatant (~900µl) was collected and transferred to a new tube. Then, 
100µl of 100% TCA was added. Samples were incubated on ice for 30 minutes and then 
centrifuged for 20 minutes at 14000rpm at 4°C. The supernatant was discarded. The pellet was 
washed with 1-1.5ml cold acetone and vortexed. Samples were then centrifuged for 15 minutes at 
14000rpm at 4°C. The supernatant was discarded and the pellet was airdried for 10-20 minutes. 
30µl of 2x SDS loading buffer was added to the samples and pipetted up and down to resuspend 
the pellet. If the solution was yellow (low pH), 1µl of 1M Tris pH 8.8 was added. Samples were 
vortexed well.  
   
SILAC Immunoprecipitation and Sample Preparation 
Immunoprecipitation  
Control and ΔGRN RAW cells were grown in carbon-13 heavy and carbon-12 light 
media, respectively, for at least seven passages. Cells were cultured in 15cm dishes. The media 
was aspirated off of the dishes and the cells were washed three times with cold PBS. 1-2ml of IP 
lysis buffer (50mM Tris-HCl, 150mM NaCl, 1% Triton, 0.1% sodium deoxycholate, and 
protease inhibitors) were added to the dishes. Cells were scraped from the dishes and the lysates 
were collected in 2ml Eppendorf tubes. Samples were centrifuged for 20 minutes at 14000rpm at 
4°C. The supernatants were transferred to new tubes and 20µl was saved as input. 20µl of sheep 
29 
 
anti-PGRN beads were added to the samples and rocked at 4°C for 4 hours. The beads were 
centrifuged at 3000rpm for 1 minute at 4°C.  20µl of the supernatants were saved. The remainder 
of the supernatant was aspirated off and the beads were washed four times with IP wash buffer 
(50mM Tris-HCl, 150mM NaCl, 1% Triton), spinning down beads at 6000rpm for 30 seconds at 
4°C.  After removing as much supernatant as possible, 40µl of elution buffer (1% SDS, 100mM 
Tris pH 8.0) were added to the samples. They were then boiled for 5 minutes and the beads were 
transferred to a filter tube. The filter tubes were spun down at 10000rpm for 1 minute. Another 
40µl of elution buffer were added to the tube originally containing the beads to ensure all beads 
were captured. The solution was then transferred to the filter tube and spun down once again at 
10000rpm for 1 minute. Samples were then analyzed by silver stain and Western blot.      
Sample Preparation  
 DTT was diluted to a final concentration of 10mM in the eluted sample and incubated at 
room temperature for 15 minutes. A 20X iodoacetamide solution (0.5M in 1M Tris pH 8.0) was 
diluted down to 1X in the samples. The heavy and light solutions were then mixed. Proteins were 
precipitated by adding three sample volumes of PPT solution (50% acetone, 49.9% ethanol, 0.1% 
acetic acid) and incubating on ice for 30 minutes. Samples were centrifuged at 14000rpm for 10 
minutes at 4°C. The supernatant was discarded and the pellet was washed with 200µl of PPT 
solution. Samples were sonicated in a water bath for 30 seconds. Samples were then centrifuged 
at 14000rpm for 10 minutes at 4°C and the supernatant was discarded. The samples were airdried 
for 5 minutes. Pellets were resuspended in 50µl of Urea/Tris (8M Urea, 50mM Tris pH 8.0) and 
then 150µl of NaCl/Tris (50mM Tris pH 8.0, 150mM NaCl). 1µg of trypsin gold (Promega) was 
added to each sample and digested overnight on a nutator set to 37°C.  
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 The next day, 5µl of 10% TFA and 5µl of 10% formic acid were added to the samples 
using a glass syringe. The pH was checked to ensure it was ~2. A Sep-Pak C18 column (Waters 
WAT054955) was conditioned with 1ml of 80% ACN and 0.1% acetic acid. The column was 
then equilibrated with 1 ml of 0.1% TFA. The sample was loaded and run through the column. 
The column was then washed twice with 1ml of 0.1% acetic acid, rinsing the syringe between the 
two additions. Samples were eluted into silanized vials with 200µl of 80% ACN and 0.1% acetic 
acid. Samples were mixed by pipetting up and down. 20µl of the sample were transferred to 
another silanized vial. Both silanized vials were dried for 40 minutes at 45°C. The 10% sample 
was resuspended in 7µl of 0.1P (0.1pmol angiotensin). 15µl of ddH2O was added to the 90% 
sample and it was frozen at -80°C. Samples were analyzed by Shannon Marshall of the Marcus 
Smolka lab.  
     
Western Blot Analysis 
 Cells were rinsed three times with cold PBS and then collected in RIPA buffer (1% 
Triton, 0.5% deoxycholate, 0.1% SDS, 150mM NaCl, 150mM Tris HCl pH 8.0, protease 
inhibitor; 100µl for a 6-well dish). Samples were sonicated and combined with 2x Laemmli 
buffer with 5% β-mercaptoethanol. Samples were heated at 95°C for five minutes before being 
loaded into a 12% SDS-PAGE gel. Samples were transferred to Immobilon-FL membranes 
(Millipore IPFL00010). Membranes were blocked for 1 hour in 5% nonfat dry milk in PBS or 
OBB. Membranes were then rinsed three times with TBS with 0.1% Tween-20 (TBST) for ten 
minutes. Primary antibodies in TBST were added the membranes and rocked overnight at 4°C. 
The membranes were rinsed with TBST three times for ten minutes. Secondary antibodies in 
TBST were then added to the membranes and rocked for 1 hour at room temperature. The 
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membranes were rinsed with TBST three times for ten minutes. Membranes were scanned on a 
LI-COR Odyssey CLx.  
 
Lysosomal Isolation 
 A Thermo Scientific Lysosome Enrichment Kit for Tissue and Cultured Cells (#89839) 
was used for lysosome purification. There are two general steps in lysosome purification: lysis of 
cells or tissue and centrifugation/purification of lysosomes. Regardless of cell or tissue 
preparation, protease inhibitor was added to Reagents A and B just prior to use. 
Cultured Cells and Sonication 
 50-200mg of cells (1-15cm dish ≈ 50mg of cells) were collected in a 2ml Eppendorf tube. 
Samples were pelleted at ~850 x g for 2 minutes at 4°C and the supernatant was discarded. 800µl 
of Reagent A were added to the samples. Samples were vortexed for 5 seconds and then 
incubated on ice for 2 minutes (did not exceed the 2-minute incubation time). Samples were 
sonicated with a Branson Digital Sonifier 450 with 3 pulses at 10% power. Cell lysis was 
confirmed by adding 5µl of lysate to a glass slide with 1µl of Trypan Blue and assessing the ratio 
of free nuclei to intracellular nuclei. A comparison to non-lysed cells can be used if needed. 
800µl Reagent B were added to the samples and tubes were inverted several times to mix. They 
were then centrifuged at 500 x g for 10 minutes at 4°C. The supernatant was collected and 
transferred to a new tube. Proceeded to density gradient centrifugation and lysosome clean-up. 
Soft Tissue and Electric Pestle Homogenization 
 In a 2ml Eppendorf tube, 50-200 mg (typically 200mg) of tissue were washed twice with 
2ml PBS and the PBS wash was discarded. The tissues were minced into small pieces with a 
razor blade and then 800µl of Reagent A were added to the samples. Homogenization was 
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performed with a Kimble Cordless Pellet Pestle (#749540-0000). The pestle attachments were 
rinsed with 70% ethanol and chilled on ice before use. Tissues were homogenized with 5 pulses. 
The lysis efficiency was then assessed by adding 5µl of lysate to a glass slide with 1µl of Trypan 
Blue and assessing the ratio of free nuclei to intracellular nuclei. This process was repeated until 
the lysis was deemed acceptable. 800µl of Reagent B were added and the tubes were inverted 
several times to mix. Samples were centrifuged at 500 x g for 10 minutes at 4°C. The supernatant 
was collected and transferred to a new tube. Proceeded to density gradient centrifugation and 
lysosome clean-up. 
Density Gradient Centrifugation and Lysosome Clean-Up 
 From the stock 60% OptiPrep solution, discontinuous gradients were created by diluting 
down the OptiPrep in Gradient Dilution Buffer (1:1 Reagent A: Reagent B). Gradients were top-
loaded into an ultracentrifuge tube, starting with the highest concentration and working down to 
the lowest concentration. Gradients used (%OptiPrep): 17, 20, 23, 27, 20 or 8, 12, 16, 19, 23, 27. 
1500µl of the prepared sample was then combined with OptiPrep so that it would lay on top of 
the density gradient (i.e. equal or lower concentration than the lowest gradient density). Samples 
were then loaded on top of the discontinuous gradient. The ultracentrifuge tubes were filled to 
the top with light mineral oil. Using a Beckman Coulter L-series ultracentrifuge with an SW 41 
Ti swinging-bucket rotor, samples were centrifuged at 141000 x g (SW 41 Ti limit) for 2 hours at 
4°C. Each fraction was collected in 1.5ml Eppendorf tubes. Enough room was left in the tubes so 
that the fractions could be diluted with 2-3 volumes of PBS. This step is crucial and single 
fractions were split into multiple tubes when collecting more than 500µl. Samples were gently 
vortexed to mix. Samples were centrifuged at 18000 x g for 30 minutes at 4°C. The supernatant 
was removed and the lysosome pellet was kept on ice. The pellet was surface-washed with 1ml 
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of Gradient Dilution Buffer and then centrifuged at 18000 x g for 30 minutes at 4°C. The 
supernatant was removed and the lysosome pellet was kept on ice for further processing. For 
these assays, samples were simply combined with 30µl of 2x Laemmli buffer with 5%  
β-mercaptoethanol and analyzed by WB.  
 
BAR Protocol 
 For labeling, an Invitrogen Biotin XX Tyramide SuperBoost Kit (#B40921) was used in 
conjunction with a donkey anti-sheep IgG secondary antibody, HRP (#A16041). Procedures were 
adapted from the accompanying manual (MAN0015834, Rev. B.0) and literature [3]. 
Validation Through Cell Staining 
 Cells on coverslips were rinsed three times with cold PBS, fixed for 15 minutes in cold 
4% PFA, and then rinsed three times with PBS. Cells were then permeabilized with 0.05% 
saponin in PBS for 30 minutes. Endogenous peroxidase activity was quenched by incubating the 
cells in 3% hydrogen peroxide for 1 hour at room temperature. Cells were rinsed three times with 
0.05% saponin in PBS. 0.05% saponin in OBB was added to samples and incubated at room 
temperature for 1 hour. Primary antibodies (e.g. sheep anti-PGRN) in OBB with 0.05% saponin 
were added to samples and incubated overnight at 4°C.  
 The following day, coverslips were rinsed three times with 0.05% saponin in PBS for 10 
minutes (30 minutes total). The poly-HRP secondary antibody (1:1000) was added to the cells 
and incubated at room temperature for 1 hour. Cells were rinsed three times with 0.05% saponin 
in PBS for 10 minutes (30 minutes total). 100µl of the working tyramide solution was applied to 
the coverslips for the designated amount of time (e.g. 2 or 5 minutes). The reaction was quenched 
with 100µl of reaction stop reagent working solution. Cells were rinsed three times with 0.05% 
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saponin in PBS for 10 minutes (30 minutes total). Secondary antibodies and Streptavidin 549 in 
OBB with 0.05% saponin were added to coverslips for 2 hours at room temperature. Coverslips 
were then rinsed three times with 0.05% saponin in PBS for 20 minutes (60 minutes total). 
Coverslips were then mounted on glass slides with Fluoromount-G.  
Validation Through Western Blot 
 Samples consisted either of cultured cells in 10cm dishes or liver tissue (50mg sections). 
The centrifugation of cells between solution changes always occurred at 2000rpm for 3 minutes. 
Cells were collected in cold 0.5mM EDTA in PBS, spun down, and rinsed twice with 
cold PBS. Cells and tissues were fixed in cold 4% PFA for 10 minutes and 2 hours, respectively. 
Samples were then spun down and rinsed three times with PBS. Samples were then 
permeabilized for 30 minutes with 0.05% saponin in PBS. Endogenous peroxidase activity was 
quenched with the addition of 3% hydrogen peroxide and subsequent 1-hour incubation. Enough 
hydrogen peroxide was added to cover the samples. Samples were rinsed three times with 0.05% 
saponin in PBS. OBB with 0.05% saponin was added to each sample and incubated at room 
temperature for 1 hour. Primary antibodies in OBB with 0.05% saponin were added to the 
samples and incubated overnight at 4°C. 
The following day, the samples were rinsed three times with 0.05% saponin in PBS for 10 
minutes (30 minutes total). The poly-HRP-conjugated secondary antibody (1:1000) was added to 
the samples and incubated at room temperature for 1 hour. Samples were rinsed three times with 
0.05% saponin in PBS for 10 minutes (30 minutes total). 100µl of tyramide working solution 
(enough to cover the samples) were applied to the samples and incubated for the designated time 
at room temperature. The reactions were quenched with the addition of 100µl of reaction stop 
reagent working solution. Samples were rinsed three times with 0.05% saponin in PBS. Sample 
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volumes were adjusted to 0.1ml PBS and 30µl of 10% SDS were added. Samples were heated for 
1 hour at 95°C with mild shaking to dissolve samples completely. Samples were heated for 
longer if samples had not completely dissolved. The samples were then centrifuged for 5 minutes 
at 14000rpm. Supernatants were collected in a new Eppendorf tube, adjusted to 1ml with PBS 
and ~10% of samples were saved as input. 25µl of streptavidin beads were added to the samples 
and incubated at room temperature for 2 hours with rocking. The beads were spun down at 
6000rpm for 30 seconds and ~10% of the supernatant was saved. The beads were washed once 
with PBS, twice with 1M NaCl in PBS, and twice more with PBS. Samples were then analyzed 
by WB.  
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